Boston Scientific (NYSE:BSX) said it finished enrolling 1,684 patients in a clinical trial of its next-generation Synergy drug-eluting stent, aiming to use the data to back regulatory nods in the U.S. and Canada.
Stent Wars
Medinol goes after J&J’s Cordis in stent patent war
Cordis Corp., the stent-making arm of Johnson & Johnson (NYSE:JNJ), got out of the coronary stent game 2 years ago, but that’s not stopping Israeli medical device company Medinol from suing Cordis for patent infringement with the Cypher and Cypher Select stents it no longer makes.
Boston Scientific legal update: Guidant, Guidezilla and ongoing arguments
Medical device giant Boston Scientific (NYSE:BSX) listed no fewer than a dozen legal battles in its latest financial report, notching some wins, some losses and some seemingly circuitous fights without end.
Stent wars: Researchers report a tie, of sorts, for Medtronic’s Resolute and Abbott’s Xience V DES
Federal Circuit again invalidates Cordis patent claims against Medtronic, Abbott, Boston Sci.
A trio of medical device giants notched another win against Johnson & Johnson(NYSE:JNJ) after a Federal Circuit judge upheld a lower court’s ruling that invalidated stent patents held by J&J subsidiary Cordis Corp.
Stentys enrolls 1st patient in U.S. stent trial
Stentys SA (EPA:STNT) hoping a new U.S. clinical trial will help it win pre-market approval for a self-apposing coronary stent.
The Princeton, N.J.- and Paris-based medical device company said it enrolled the 1st patient in its Apposition V trial, under an investigational device exemption from the U.S. watchdog agency.
Boston Scientific denies OrbusNeich accusations
German court issues 2nd injunction against Boston Scientific in OrbusNeich stent patent spat
OrbusNeich blocks German imports of Boston Scientific’s stents
OrbusNeich Medical wasted no time in enforcing a patent win against Boston Scientific (NYSE:BSX), announcing that it is blocking German imports of its rival’s cardiac stents.
German court grants OrbusNeich injunction over Boston Scientific in stents patent row
UPDATED April 30, 2013 with analyst’s reaction; comment from Boston Scientific.
OrbusNeich Medical said a German court granted a preliminary injunction against Boston Scientific (NYSE:BSX) in a legal war over coronary stent patents.
J&J’s Cordis escapes $593M stent patent infringement loss
Johnson & Johnson (NYSE:JNJ) logged a major win for its Cordis stent-making arm today when a federal appeals court overturned a lower court decision to award more than $593 million to stent pioneer Dr. Bruce Saffran for patent infringement.
Saffran alleged that Cordis violated his patent with the Cypher drug-eluting stent, leading to a jury trial that went Saffran’s way.